The Regulatory Event That Changes U.S. Sunscreen Formulation

On June 9, 2026, the FDA finalized approval of bemotrizinol, also known as BEMT or PARSOL Shield, as an active ingredient for over-the-counter sunscreens in the United States. This marks the first new UV filter approval in the U.S. market in over 25 years.

For anyone working in sunscreen formulation, brand development, regulatory affairs, beauty innovation, or market strategy, this is not a small technical update. It is a category-shaping regulatory event that deserves immediate attention.

Bemotrizinol has been used for years in Europe, Australia, and Asia under names including Tinosorb S. Its U.S. approval opens the door to new sunscreen textures, stronger UVA protection strategies, and more globally aligned formulas for American consumers.

This post breaks down what the approval means, what the timeline looks like, and where the biggest strategic opportunities and constraints are for brands and formulators.

The Regulatory Structure: What Changed and Why

Sunscreens in the United States are regulated as over-the-counter drugs under the FDA’s OTC Monograph system. That means sunscreen active ingredients must meet FDA standards for safety and efficacy before they can be used in U.S. products.

New active ingredients require a separate regulatory pathway through an OTC Monograph Order Request, or OMOR. DSM-Firmenich submitted its OMOR for bemotrizinol in October 2024. The FDA published a proposed order in late 2025, accepted public comment, and finalized the approval on June 9, 2026.

The final order allows bemotrizinol to be used in OTC sunscreen products sold in the United States. The order becomes effective on August 9, 2026.

DSM-Firmenich also holds an 18-month market exclusivity period for PARSOL Shield. During this period, brands planning U.S. bemotrizinol launches will need to account for supply access, formulation timelines, stability testing, claims strategy, and launch sequencing.

For strategic planners, this matters now. The brands that treat this as a 2026 product development priority will be better positioned than brands that wait until the ingredient is already on shelves.

What Bemotrizinol Offers Formulators

For formulators who have been working within the limits of the existing U.S. UV filter toolkit, bemotrizinol represents a meaningful upgrade.

Its key formulation advantages include:

Broad-spectrum UVA and UVB absorption. Bemotrizinol absorbs across both UVA and UVB ranges, with absorption peaks around 310 nm and 340 nm. This makes it especially useful in building stronger broad-spectrum protection.

Strong photostability. Unlike avobenzone, bemotrizinol is highly photostable and does not rapidly degrade under UV exposure. This gives formulators more flexibility and may reduce dependence on stabilizing systems such as octocrylene.

Support for more elegant textures. Bemotrizinol can help formulators achieve high SPF and broad-spectrum protection without relying as heavily on older filter combinations that can feel greasy, heavy, or cosmetically limited.

Low systemic absorption profile. Bemotrizinol is lipophilic, has very low water solubility, and has a larger molecular structure that limits skin penetration. In a consumer environment where many people are increasingly skeptical of chemical filter absorption, this is a meaningful communication advantage.

Compatibility with modern sunscreen positioning. Bemotrizinol fits well into products positioned around daily wear, high UVA protection, cosmetic elegance, sensitive skin, and global sunscreen technology.

For U.S. sunscreen development, this is not just another active ingredient. It gives formulators a new way to solve some of the most persistent weaknesses in the American sunscreen market.

Where Bemotrizinol Creates the Most Value

For brand and product development teams, the highest-value opportunities are likely to fall into several categories.

1. High-SPF Lightweight Facial Sunscreens

The U.S. has long lagged behind Asia and Europe in elegant high-SPF facial sunscreens. Many American formulas still feel heavier, greasier, or less cosmetically refined than the sunscreens consumers import from Korea, Japan, Europe, and Australia.

Bemotrizinol changes the formulation equation.

Because it provides broad-spectrum coverage and strong photostability, it may help brands develop SPF 50 and SPF 50+ facial sunscreens with lighter textures, better spreadability, and more daily-wear appeal.

This is likely to be the most consumer-visible category. The biggest early wins will probably come from facial sunscreens that feel like skincare, sit well under makeup, and solve the common complaint that American sunscreens are effective but unpleasant to use.

2. Korean Beauty and Global Formula Alignment

This may be the most commercially significant near-term opportunity.

Many Korean and international sunscreen brands have had to create separate U.S.-market formulas because their original global formulas used filters that were not FDA-approved. In many cases, that meant removing Tinosorb S or related modern UV filters and replacing them with older U.S.-approved alternatives.

The result was often a U.S. product that looked like the global version, but did not feel or perform the same way.

Bemotrizinol’s approval removes one major barrier. It does not automatically make every global sunscreen formula U.S.-compliant, since many international formulas use multiple UV filters that may still not be FDA-approved. But it does make U.S. reformulation much more realistic and much more exciting.

For K-beauty brands, this is a major opportunity to better serve the highly engaged American consumer who already knows that international sunscreen textures are often more elegant.

3. Sensitive Skin and Pediatric Sunscreens

Bemotrizinol’s low absorption profile and long history of use internationally make it a strong candidate for sensitive skin and pediatric sunscreen categories.

Parents and sensitive-skin consumers are often cautious about sunscreen filters. They want products that feel good, protect well, and are easy to use consistently, but they also want reassurance around safety.

The FDA approval includes use in adults and children 6 months and older. That gives brands a clear path to develop family-friendly and sensitive-skin products with more modern chemical filter technology.

This category will require careful messaging. The strongest positioning will likely focus on broad-spectrum protection, photostability, tolerability, and daily usability rather than fear-based comparisons to other sunscreen ingredients.

4. Skin of Color-Focused Sunscreens

For skin of color consumers, sunscreen adherence is often affected by cosmetic elegance. White cast, heaviness, pilling, and poor compatibility with deeper skin tones are major barriers to daily use.

Bemotrizinol is a chemical UV filter, so it does not create the same white cast concerns associated with mineral-only formulas. That makes it especially relevant for brands focused on melanin-rich skin.

The UVA protection story also matters clinically. UVA contributes to photoaging, pigmentary disorders, and worsening of hyperpigmentation, melasma, and post-inflammatory hyperpigmentation. Brands that can pair strong UVA protection with elegant, no-white-cast textures will have a compelling message for both consumers and dermatologists.

Competitive Landscape During the Exclusivity Period

The 18-month exclusivity period creates a structured competitive window.

Brands with existing DSM-Firmenich relationships, or brands that move quickly to establish them, may have a first-mover advantage in the U.S. bemotrizinol market. Those that wait may find themselves entering after the initial wave of consumer and media excitement has already passed.

Strategic questions brands should be asking now include:

  • Do we already have a supply relationship with DSM-Firmenich?
  • Which existing global formulas contain BEMT or Tinosorb S?
  • Which products could be reformulated for the U.S. market using bemotrizinol?
  • What is the lead time for formulation development, stability testing, OTC labeling review, packaging updates, and retail launch?
  • Can we launch while consumer awareness is still high?
  • Do we have dermatologist, chemist, or KOL partners who can explain why this ingredient matters?

After exclusivity ends, more suppliers may be able to enter the market. At that point, the ingredient itself may become less differentiating. The early competitive advantage will likely belong to brands that can translate bemotrizinol into better formulas, clearer education, and faster consumer trust.

Consumer Communication Strategy

The FDA approval has already generated significant media attention. Consumer awareness of bemotrizinol is higher now than it has ever been in the U.S.

That creates a rare launch moment. The strongest consumer messaging will likely focus on three themes.

First, bemotrizinol has been used safely in Europe and other global markets for years, and it is now available for U.S. sunscreen formulation.

Second, it is highly photostable, meaning it holds up well under UV exposure.

Third, it may help make U.S. sunscreens more elegant, lighter, and easier to wear daily.

For dermatologist-led education, the most clinically compelling message is improved broad-spectrum protection, especially UVA coverage. For beauty consumers, the most compelling message may be texture. For K-beauty consumers, it is the possibility of finally narrowing the gap between U.S. formulas and the global sunscreens they already know and love.

Brands should avoid overstating the approval. Bemotrizinol does not mean every international sunscreen can immediately come to the U.S. unchanged. It also does not mean older sunscreen ingredients are ineffective. The better message is that U.S. formulators now have a stronger and more modern tool to work with.

What Brands Should Do Now

For sunscreen brands, this is the time to act.

The most important next steps are:

  • Audit your global formulas for BEMT or Tinosorb S.
  • Identify U.S. SKUs that could benefit from reformulation.
  • Begin supplier conversations early.
  • Map stability, packaging, labeling, and launch timelines.
  • Build consumer education around photostability, UVA protection, and cosmetic elegance.
  • Prepare dermatologist and formulator-facing content before the first products arrive.

The U.S. sunscreen market has been waiting for a regulatory shift like this for decades. Bemotrizinol will not solve every formulation challenge, but it gives brands a powerful new tool at exactly the moment when consumers are asking for better sunscreen.

For formulators, this is a technical breakthrough. For brands, it is a market opportunity. For consumers, it may finally mean access to sunscreens that protect well and feel good enough to wear every day.

Bottom Line

Bemotrizinol’s FDA approval is one of the most important U.S. sunscreen developments in a generation.

It gives formulators a modern, photostable, broad-spectrum UV filter. It gives brands a new path toward elegant high-SPF facial sunscreens. It gives Korean and global beauty brands a clearer route to more aligned U.S. formulas. And it gives consumers the possibility of better daily sun protection options.

The brands that move quickly, communicate clearly, and formulate thoughtfully will define the next chapter of the U.S. sunscreen market.

Updated June 2026